From: Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
 | Inspiratory capacity, L | p-value | ||
---|---|---|---|---|
 | NVA237 50 μg (n = 534) | Placebo (n = 260) | Difference |  |
Day 1 | Â | Â | Â | Â |
   25 min | 2.110 ± 0.0148 | 1.930 ± 0.0194 | 0.181 ± 0.0212 | < 0.001 |
   1 h 55 min | 2.166 ± 0.0157 | 1.978 ± 0.0210 | 0.189 ± 0.0230 | < 0.001 |
   3 h 55 min | 2.139 ± 0.0164 | 1.970 ± 0.0217 | 0.169 ± 0.0232 | < 0.001 |
   23 h 40 min | 2.019 ± 0.0168 | 1.915 ± 0.0222 | 0.104 ± 0.0239 | < 0.001 |
Week 12 | Â | Â | Â | Â |
   -20 min | 1.967 ± 0.0221 | 1.883 ± 0.0281 | 0.084 ± 0.0286 | 0.003 |
   25 min | 2.048 ± 0.0216 | 1.900 ± 0.0274 | 0.148 ± 0.0278 | < 0.001 |
   1 h 55 min | 2.103 ± 0.0232 | 1.923 ± 0.0297 | 0.180 ± 0.0305 | < 0.001 |
   3 h 55 min | 2.040 ± 0.0218 | 1.898 ± 0.0285 | 0.142 ± 0.0300 | < 0.001 |
   23 h 40 min | 2.009 ± 0.0212 | 1.912 ± 0.0282 | 0.097 ± 0.0296 | < 0.001 |
Week 26 | Â | Â | Â | Â |
   -20 min | 1.988 ± 0.0202 | 1.879 ± 0.0267 | 0.109 ± 0.0281 | < 0.001 |
   25 min | 2.055 ± 0.0205 | 1.905 ± 0.0272 | 0.150 ± 0.0285 | < 0.001 |
   1 h 55 min | 2.107 ± 0.0214 | 1.929 ± 0.0288 | 0.178 ± 0.0309 | < 0.001 |
   3 h 55 min | 2.080 ± 0.0206 | 1.915 ± 0.0283 | 0.165 ± 0.0304 | < 0.001 |
   23 h 40 min | 1.997 ± 0.0192 | 1.884 ± 0.0257 | 0.113 ± 0.0275 | < 0.001 |